RT Journal Article
SR Electronic
T1 Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4535
OP 4542
DO 10.21873/anticanres.15265
VO 41
IS 9
A1 GIANLUCA VANNI
A1 MARCO PELLICCIARO
A1 FRANCESCA COMBI
A1 SIMONA PAPI
A1 MARCO MATERAZZO
A1 SILVIA SEGATTINI
A1 STEFANO RIZZA
A1 MARCELLO CHIOCCHI
A1 TOMMASO PERRETTA
A1 ROSARIA MEUCCI
A1 ILARIA PORTARENA
A1 CHIARA ADRIANA PISTOLESE
A1 BENEDETTO IELPO
A1 MICHELA CAMPANELLI
A1 GIORGIO LISI
A1 AGOSTINO CHIARAVALLOTI
A1 GIOVANNI TAZZIOLI
A1 ORESTE CLAUDIO BUONOMO
YR 2021
UL http://ar.iiarjournals.org/content/41/9/4535.abstract
AB Background/Aim: Due to the SARS-CoV-2 pandemic, many scientific committees proposed neoadjuvant therapy (NACT) bridging treatment as a novel strategy and indication. The aim of the study was to evaluate the impact of COVID-19 pandemic on breast cancer patients undergoing NACT. Patients and Methods: All breast cancer patients referred to two Breast Units during COVID-19-pandemic were enrolled. Results: Out of 814 patients, 43(5.3%) were enrolled in the COVID-19-group and compared with 94 (7.9%) similar Pre-COVID-19 patients. We observed a reduction in the number of patients undergoing NACT, p=0.0019. No difference was reported in terms of clinical presentation, indications, and tumor response. In contrast, a higher number of vascular adverse events was reported (6.9% vs. 0% p=0.029). Immediate breast cancer reconstructions following invasive surgery suffered a significant slowdown (5.9% vs. 47.7%, p=0.019). Conclusion: COVID-19 caused a reduction in the number of patients undergoing NACT, with no changes in terms of indications, clinical presentation, and tumor response. Furthermore, there was an increased incidence of vascular events.